Evidence map›Paper›PMID 29786049›Full record

ArticleChinese medical journal2018

Lipoxin A4 Ameliorates Lipopolysaccharide-Induced A549 Cell Injury through Upregulation of N-myc Downstream-Regulated Gene-1.

Jun-Zhi Zhang, Zhan-Li Liu, Yao-Xian Zhang, Hai-Jiu Lin, Zhong-Jun Zhang

Open access · goldAbstract read
In one paragraph

Article in Chinese medical journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jun-Zhi ZhangDepartment of Anesthesiology, 2nd Clinical Medical College of Jinan University; Department of Anesthesiology, Shenzhen People's Hospital, Shenzhen, Guangdong 518020, China.
Zhan-Li LiuDepartment of Anesthesiology, 2nd Clinical Medical College of Jinan University; Department of Anesthesiology, Shenzhen People's Hospital, Shenzhen, Guangdong 518020, China.
Yao-Xian ZhangDepartment of Anesthesiology, 2nd Clinical Medical College of Jinan University; Department of Anesthesiology, Shenzhen People's Hospital, Shenzhen, Guangdong 518020, China.
Hai-Jiu LinResearch and Development Department, Shenzhen Acen Regenerative Medicine, Shenzhen, Guangdong 518122, China.
Zhong-Jun ZhangDepartment of Anesthesiology, 2nd Clinical Medical College of Jinan University; Department of Anesthesiology, Shenzhen People's Hospital, Shenzhen, Guangdong 518020, China.
ShenZhen People’s Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLipoxin A4 (LXA4) can alleviate lipopolysaccharide (LPS)-induced acute lung injury (ALI) and acute respiratory distress syndrome through promoting epithelial sodium channel (ENaC) expression in lung epithelial cells. However, how LXA4 promote ENaC expression is still largely elusive. The present study aimed to explore genes and signaling pathway involved in regulating ENaC expression induced by LXA4.

methodsA549 cells were incubated with LPS and LXA4, or in combination, and analyzed by quantitative real-time polymerase chain reaction (qRT-PCR) of ENaC-α/γ. Candidate genes affected by LXA4 were explored by transcriptome sequencing of A549 cells. The critical candidate gene was validated by qRT-PCR and Western blot analysis of A549 cells treated with LPS and LXA4 at different concentrations and time intervals. LXA4 receptor (ALX) inhibitor BOC-2 was used to test induction of candidate gene by LXA4. Candidate gene siRNA was adopted to analyze its influence on A549 viability and ENaC-α expression. Phosphoinositide 3-kinase (PI3K) inhibitor LY294002 was utilized to probe whether the PI3K signaling pathway was involved in LXA4 induction of candidate gene expression.

resultsThe A549 cell models of ALI were constructed and subjected to transcriptome sequencing. Among candidate genes, N-myc downstream-regulated gene-1 (NDRG1) was validated by real-time-PCR and Western blot. NDRG1 mRNA was elevated in a dose-dependent manner of LXA4, whereas BOC-2 antagonized NDRG1 expression induced by LXA4. NDRG1 siRNA suppressed viability of LPS-treated A549 cells (treatment vs. control, 0.605 ± 0.063 vs. 0.878 ± 0.083, P = 0.040) and ENaC-α expression (treatment vs. control, 0.458 ± 0.038 vs. 0.711 ± 0.035, P = 0.008). LY294002 inhibited NDRG1 (treatment vs. control, 0.459 ± 0.023 vs. 0.726 ± 0.020, P = 0.001) and ENaC-α (treatment vs. control, 0.236 ± 0.021 vs. 0.814 ± 0.025, P < 0.001) expressions and serum- and glucocorticoid-inducible kinase 1 phosphorylation (treatment vs. control, 0.442 ± 0.024 vs. 1.046 ± 0.082, P = 0.002), indicating the PI3K signaling pathway was involved in regulating NDRG1 expression induced by LXA4.

conclusionOur research uncovered a critical role of NDRG1 in LXA4 alleviation of LPS-induced A549 cell injury through mediating PI3K signaling to restore ENaC expression.

Indexed as

A549 CellsAcute Lung InjuryCell Cycle ProteinsCell LineEpithelial Sodium ChannelsHumansIntracellular Signaling Peptides and ProteinsLipopolysaccharidesLipoxinsN-myc Downstream-Regulated Gene 1 ProteinSignal TransductionCell Cycle ProteinsEpithelial Sodium ChannelsIntracellular Signaling Peptides and ProteinsLipopolysaccharideslipoxin A4LipoxinsN-myc Downstream-Regulated Gene 1 ProteinAcute Lung InjuryEpithelial Sodium ChannelLipopolysaccharideLipoxin A4N-myc Downstream-Regulated Gene-1

Identifiers

PMID29786049
PMCPMC5987507
OpenAlexW2803537534

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.